Tara Williamson et al., 2021-07-06: Williamson et al. test mebendazole in KC and KPC mouse models of pancreatic cancer, reporting less dysplasia, less stromal desmoplasia, smaller tumours and fewer liver metastases.
In the early intervention study, treated mice began receiving daily 35 mg/kg mebendazole (polymorph C) in the feed starting at 5 weeks of age.
Tara Williamson et al., 2021-07-06: Williamson et al. test mebendazole in KC and KPC mouse models of pancreatic cancer, reporting less dysplasia, less stromal desmoplasia, smaller tumours and fewer liver metastases. Study type: Kras-driven KC and KPC mouse models of pancreatic cancer. N: not stated in the abstract; groups per model. Country: USA (Johns Hopkins). Dose: 35 mg/kg/day polymorph C in feed with sesame oil, started at 5 weeks (early) or 10 weeks (late). Funder: not stated in the record. Declared conflicts: 'Authors have no conflicts of interest to declare.' Comparator: control diet, in early and late intervention designs. Study type: animal.
